Both the CDC and WHO say preliminary UK data show the current flu vaccine offers strong protection against subclade K.
Different bacteria, viruses, and fungi have been suggested as possible causative pathogens for Parkinson’s.
The comments centered on a memo from FDA Center for Biologics Evaluation and Research Director Vinay Prasad.
Just 34% of US adults have gotten a flu shot, 25% have had a COVID vaccine, 8% have received the pneumococcal vaccine, and 6% have been vaccinated against RSV.
Vinay Prasad claimed—but provided no evidence—that COVID-19 vaccines caused the death of 10 children.
The vaccine was fully protective in a small human challenge model, showing superior efficacy to the conventional 4-strain flu vaccine.
In a phase 3 trial, participants who received the shot were 29% less likely to be diagnosed with flu than those who received a conventional flu shot.
Early data from the UK and Japan show that the H3N2 subclade K was represented in 90% of flu samples.
High-dose vaccine was 40% more effective against hospitalization than the standard-dose version.
Our systematic review published this week shows that rigorous, transparent evidence synthesis can persist even when traditional advisory processes falter.
